Form 4: Karyopharm Therapeutics Executive Sells Shares to Cover Tax Obligations

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold 2,883 shares of common stock to cover withholding tax liabilities.

Summary

• On July 30, 2024, Stuart Poulton, the EVP and Chief Development Officer of Karyopharm Therapeutics Inc., sold 2,883 shares of common stock at a price of $1.06 per share.
• The sale was executed under a pre-arranged automatic sale instruction plan adopted on May 18, 2022.
• The purpose of the sale was to cover the withholding tax liability incurred upon the vesting of restricted stock units.
• Following the transaction, Poulton directly owns 326,628 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax purposes) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax obligations. The use of a pre-arranged trading plan (Rule 10b5-1) is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of tax obligations and the pre-arranged trading plan.

Key Dates